

One-Pot Organocatalytic Enantioselective Domino Double-Michael Reaction and Pictet-Spengler–Lactamization Reaction. A Facile Entry to the “Inside Yohimbane” System with Five Contiguous Stereogenic Centers


Bor-Cherng Hong,* Wei-Kai Liao, Nitin S. Dange, and Ju-Hsiou Liao

Department of Chemistry and Biochemistry, National Chung Cheng University,
Chia-Yi, 621 Taiwan, R.O.C.

chebch@ccu.edu.tw

Received November 23, 2012

ABSTRACT



An expedited method was developed for the enantioselective synthesis of dodecahydrobenz[a]indolo[3,2-*h*]quinolizine containing five contiguous stereogenic centers with high enantioselectivities (>99% ee). The methodology comprises a domino organocatalytic double Michael reaction and Pictet-Spengler–lactamization reaction. The structures and absolute configurations of the appropriate products were confirmed by X-ray analysis.

The quinolizidine alkaloids represent an important class of alkaloids with a wide spectrum of biological activities and have long attracted extensive pharmacological, chemical, and synthetic interests.¹ Among these compounds, the dodecahydrobenz[a]indolo[3,2-*h*]quinolizine, the so-called “inside yohimbane”, emerged as a preeminent member of this alkaloid category. Examples of natural and synthetic compounds bearing the dodecahydrobenz[a]indolo[3,2-*h*]quinolizine skeleton have shown various biological activities (Figure 1). Manadomanzamine A and manadomanzamine B have anti HIV, antifungal,

antimycobacterial, and cytotoxic activities;² 21a-homo-14-nor-yohimba-15,17,19-triene has high affinity for the α 1 adrenergic receptors;³ 2,3,4,4a β ,5,6,7,8,13,13b β -decahydro-1*H*-6a,13-diazaindeno[1,2-*c*]phenanthren-13c β -ol has high affinity for the α 2C-adrenoceptor;⁴ pentacyclic benzindoloquinolizine has been reported to have antiserotonergic effects.⁵ The inside α -yohimbine intermediates have been prepared following the method for the total synthesis of reserpine and α -yohimbane.⁶ Although several synthetic approaches toward the “inside yohimbane” skeleton have

(1) For a review, see: (a) Michael, J. P. *Nat. Prod. Rep.* **2008**, 139–165 and the proceeding 11 reviews in the series of indolizidine and quinolizidine alkaloids by Michael cited therein.

(2) (a) Peng, J.; Hu, J.-F.; Kazi, A. B.; Li, Z.; Avery, M.; Peraud, O.; Hill, R. T.; Franzblau, S. G.; Zhang, F.; Schinazi, R. F.; Wirtz, S. S.; Tharnish, P.; Kelly, M.; Wahyuono, S.; Mark T. Hamann, M. T. *J. Am. Chem. Soc.* **2003**, 125, 13382–13386. (b) Rao, K. V.; Donia, M. S.; Peng, J.; Garcia-Palomo, E.; Alonso, D.; Martinez, A.; Medina, M.; Franzblau, S. G.; Tekwani, B. L.; Khan, S. I.; Wahyuono, S.; Willett, K. L.; Hamann, M. T. *J. Nat. Prod.* **2006**, 69, 1034–1040.

(3) (a) Hoefgen, B.; Decker, M.; Mohr, P.; Schramm, A. M.; Rostom, S. A. F.; El-Subbagh, H.; Schweikert, P. M.; Rudolf, D. R.; Kassack, M. U.; Lehmann, J. *J. Med. Chem.* **2006**, 49, 760–769. (b) Abadi, A. H.; Lankow, S.; Hoefgen, B.; Decker, M.; Kassack, M. U.; Lehmann, J. *Arch. Pharm.* **2002**, 335, 367–373. (c) Witt, T.; Hock, F. J.; Lehmann, J. *J. Med. Chem.* **2000**, 43, 2079–2081. (d) Tourwe, D.; Cock, E. D.; Binst, G. V. *J. Org. Chem.* **1981**, 46, 5321–5324.

(4) Orion Corporation, WO2003/82866 A1, 2003.

(5) Enzensperger, C.; Kilian, S.; Ackermann, M.; Koch, A.; Kelch, K.; Lehmann, J. *Bioorg. Med. Chem. Lett.* **2007**, 17, 1399–1402. (b) Enzensperger, C.; Lehmann, J.; Schroetter, K.; Riyazi, A.; Verspohl, E. *J. Arzneimittelforschung* **2010**, 60, 544–552.

been reported,⁷ the construction of this pentacyclic ring system with five stereogenic centers in a cascade strategy with high enantioselectivity remains elusive. An efficient synthetic methodology toward this system with suitable functionality is certainly attractive and would be useful for discovering pharmaceutical lead compounds.





Figure 1. Select examples of the biologically active natural products and synthetic compounds with dodecahydrobenz[a]indolo[3,2-h]quinolizine skeleton.

Scheme 1. Retrosynthetic Analysis of Dodecahydrobenz[a]indolo[3,2-h]quinolizine



(6) Martin, S. F.; Rueger, H.; Williamson, S. A.; Grzejszczak, S. *J. Am. Chem. Soc.* **1987**, *109*, 6124–6134.

(7) (a) Allin, S. M.; Duffy, L. J.; Page, P. C. B.; McKee, V.; McKenzie, M. J. *Tetrahedron Lett.* **2007**, *48*, 4711–4714. (b) Allin, S. M.; Duffy, L. J.; Towler, J. M. R.; Page, P. C. B.; Elsegood, M. R. J.; Saha, B. *Tetrahedron* **2009**, *65*, 10230–10234. (c) Morrison, G. C.; Cetenko, W. A.; Shavel, J. *J. Org. Chem.* **1967**, *32*, 2768–2772. (d) Martin, S. F.; Rueger, H.; Williamson, S. A.; Grzejszczak, S. *J. Am. Chem. Soc.* **1987**, *109*, 6124–6134. (e) Yan, L.-H.; Nuhant, P.; Sinigaglia, I.; Fromentin, Y.; Marazano, C.; Delpech, B.; Poupon, E. *Eur. J. Org. Chem.* **2012**, 1147–1157.

Table 1. Screening of the Catalysts, Solvents, and Reaction Conditions for the Stereoselective Double Michael Reaction^a

entry	cat. + additive	solvent	time (h)	yield ^{b,c} (%)
1	I–DABCO	CHCl ₃	7	84
2	II–DABCO	CHCl ₃	96	50
3	III–DABCO	CHCl ₃	96	nr
4	IV–DABCO	CHCl ₃	44	83 ^d
5	V–DABCO	CHCl ₃	96	0
6	VI–DABCO	CHCl ₃	96	56
7	VII–DABCO	CHCl ₃	19	15
8	VIII–DABCO	CHCl ₃	41	trace
9	IV–DABCO	toluene	96	41
10	IV–DABCO	CH ₂ Cl ₂	64	89 ^d
11	IV–DABCO	THF	72	80
12	IV–DABCO	EtOH ^e	10	90 ^{d,f}
13	IV–DABCO	DMF	96	71
14	IV–DABCO	CH ₃ CN	61	90 ^{d,g}
15	IV–DABCO	1,4-dioxane	96	59
16	IV–Et ₃ N	CH ₂ Cl ₂	43	68
17	IV–NaOAc	CH ₂ Cl ₂	39	62
18	IV–DBU	CH ₂ Cl ₂	18	65
19	IV–2,6-lutidine	CH ₂ Cl ₂	39	65
20	IV–HOAc	CH ₂ Cl ₂	39	41

^a Unless otherwise noted, the reactions were performed on a 0.1 mmol scale of **3a** and **4a** (1.2 equiv) using 20 mol % of the catalyst and additive at ambient temperature in a vial containing the appropriate solvent. ^b Isolated yields of **5a**. ^c Unless otherwise noted, diastereomeric ratio > 20:1, determined by ¹H NMR of the reaction mixture. ^d > 99% ee of **5a**, determined by HPLC with chiral column Chiralpak IA. ^e 99% ethanol. ^f Diastereomeric ratio 16:1. ^g Diastereomeric ratio 17:1, nr = no reaction.

Prompted by the above background and in the context of our ongoing investigations in organocatalyzed annulations,^{8,9} we envisioned that the lactamization and Pictet–Spengler¹⁰ transformation of the “inside yohimbane” system


(8) For a recent review of organocatalyzed cycloadditions, see: Hong, B.-C. In *Enantioselective Organocatalyzed Reactions II*; Mahwald, R., Ed.; Springer: Dordrecht, 2011; Chapter 3, pp 187–244.

(9) (a) Hong, B.-C.; Dange, N. S.; Yen, P.-J.; Lee, G.-H.; Liao, J.-H. *Org. Lett.* **2012**, *14*, 5346–5349. (b) Hong, B.-C.; Chen, P.-Y.; Kotame, P.; Lu, P.-Y.; Lee, G.-H.; Liao, J.-H. *Chem. Commun.* **2012**, *48*, 7790–7792. (c) Hong, B.-C.; Dange, N. S.; Ding, C.-F.; Liao, J.-H. *Org. Lett.* **2012**, *14*, 448–451. (d) Hong, B.-C.; Hsu, C.-S.; Lee, G.-H. *Chem. Commun.* **2012**, *48*, 2385–2387. (e) Hong, B.-C.; Kotame, P.; Lee, G.-H. *Org. Lett.* **2011**, *13*, 5758–5761. (f) Hong, B.-C.; Dange, N. S.; Hsu, C.-S.; Liao, J.-H.; Lee, G.-H. *Org. Lett.* **2011**, *13*, 1338–1341. (g) Hong, B.-C.; Nimje, R. Y.; Lin, C.-W.; Liao, J.-H. *Org. Lett.* **2011**, *13*, 1278–1281. (h) Hong, B.-C.; Dange, N. S.; Hsu, C.-S.; Liao, J.-H. *Org. Lett.* **2010**, *12*, 4812–4815. (i) Hong, B.-C.; Kotame, P.; Tsai, C.-W.; Liao, J.-H. *Org. Lett.* **2010**, *12*, 776–779. (j) Kotame, P.; Hong, B.-C.; Liao, J.-H. *Tetrahedron Lett.* **2009**, *50*, 704–707 and references cited therein.

(10) For recent reviews of Pictet–Spengler reactions, see: (a) Larghi, E. L.; Kaufman, T. S. *Eur. J. Org. Chem.* **2011**, 5195–5231. (b) Stöckigt, J.; Antonchick, A. P.; Wu, F.; Waldmann, H. *Angew. Chem., Int. Ed.* **2011**, *50*, 8538–8564. (c) Agarwal, P. K.; Sawant, D.; Sharma, S.; Kundu, B. *Eur. J. Org. Chem.* **2009**, 292–303.

1 would lead to the precursor, cyclohexylcarbaldehyde **2**, which could be efficiently prepared via a domino organo-catalyzed double Michael reaction¹¹ of the suitable nitro alkenoate **3** and α,β -unsaturated aldehyde **4** (Scheme 1). We report herein the development of a one-pot organocatalytic enantioselective domino double-Michael reaction and Pictet–Spengler–lactamization reaction sequence leading to dodecahydrobenz[*a*]indolo[3,2-*h*]quinolizines in good yields and excellent diastereoselectivities and enantioselectivities (up to >99% ee).

Table 2. Scope of Organocatalytic Double-Michael–Pictet–Spengler Reactions^a



entry	R ₁	R ₂	time ^b (h)	yield ^{c, d} (%)	ee ^e (%)
1	7a , C ₆ H ₅	H	34	77	>99
2	7b , 4-FC ₆ H ₄	H	36	82	>99
3	7c , 4-ClC ₆ H ₄	H	25	83	>99
4	7d , 4-BrC ₆ H ₄	H	36	62	>99
5	7e , 4-NO ₂ C ₆ H ₄	H	26	77	>99
6	7f , 4-MeOC ₆ H ₄	H	36	82	>99
7	7g , 4-NMe ₂ C ₆ H ₄	H	31	84	>99
8	7h , 2-MeC ₆ H ₄	H	168	76	>99
9	7i , 4-MeC ₆ H ₄	H	25	83	>99
10	7j , 2-furyl	H	44	65	>99
11	7k , C ₆ H ₅	OMe	38	86	>99

^a Unless otherwise noted, the reactions were performed on a 0.2 mmol scale of **3** and **4**, in a ratio of 1:1.2, using 20 mol % of the catalyst **IV** and DABCO at room temperature in a vial containing the appropriate solvent.

^b Time required for 1st–double Michael reaction. ^c Isolated yield of **7**.

^d Diastereomeric ratio > 20:1, determined by ¹H NMR of crude reaction mixture. ^e The ee of **7**, determined by HPLC with Chiralpak IA.

Initially, the double Michael reaction of nitroalkenoate **3** and cinnamaldehyde **4a** was performed with pyrrolidine (**I**)–DABCO in CHCl₃ at ambient temperature for 7 h and provided the cyclohexylcarbaldehyde **5a** in 84% yield (Table 1, entry 1). After the reactions were screened with other catalysts, e.g., **II**–**VIII**, the best result was obtained with the condition of **IV**–DABCO for 44 h reaction to give 83% yield of **5a** with >99% ee (Table 1, entry 4). The reactions with other catalysts afforded much lower yield, or there was no observation of product **5a** (Table 1, entries 1–8). Further optimization of the double-Michael reaction with **IV**–DABCO in various solvents was conducted, and the optimal yield of **5a** was obtained in 89% yield

with >99% ee for the reaction in CH₂Cl₂ (Table 1, entries 9–15 and entry 10). The reactions in 99% EtOH or CH₃CN gave slightly lower diastereoselectivity (Table 1, entries 12 and 14). Reactions performed with catalysts **IV** and other additives were not promising and provided lower yields (Table 1, entries 16–20).

The Pictet–Spengler reaction and lactamization was achieved by the reaction of **5a**, isolated from the reaction depicted in Table 1, and 1.5 equiv of 2-(1*H*-indol-3-yl)-ethanamine (**6a**) with 1.4 equiv of trifluoroacetic acid (TFA) in refluxing toluene for 1 h to give 73% yield of **7a**. Notably, the domino reaction sequence, the double-Michael, and the Pictet–Spengler reactions could be achieved in one pot without the need to isolate the double Michael adducts **5a**. The one-pot reaction strategy was achieved via the addition of toluene in the reaction mixtures after the completion of double Michael reaction in CH₂Cl₂, followed by treatment with **6a** and TFA, to provide 77% yield of **7a** with >99% ee. In addition, the one-pot process provided a slightly better yield than that obtained with the isolation of **5a** and the resubmission sequence of the Pictet–Spengler–lactamization reaction (Table 2, entry 1). With the optimized conditions in hand, the one-pot domino-reaction protocol was applied in the reaction with various α,β -unsaturated aldehydes **4**, and the results were promising and general with high yields and stereoselectivities (Table 2). Usually, the reaction was completed in 2 days, but a much longer reaction time was required in the case with **4h** bearing the *ortho*-substituent. The steric bulkiness so close to the conjugate addition center may encumber the reactions (Table 2, entry 8). The structures of the adducts were assigned on the basis of the X-ray analysis of a single crystal of (–)-**7a** (Figure 1).¹² In particular, the absolute configurations of the products were unambiguously determined by the X-ray analysis of (–)-**7c** (Figure 2).¹³





Figure 2. Stereoplots of the X-ray crystal structures of (–)-**7a** and (–)-**7c**: C, gray; O, red; N, blue; Cl, green.

(12) X-ray crystal structure analysis of (–)-**7a**: C₂₅H₂₅N₃O₃, weight 415.48 g mol^{–1}, colorless crystal. CCDC-909086 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif


(13) X-ray crystal structure analysis of (–)-**7c**: C₂₅H₂₄ClN₃O₃, weight 449.92 g mol^{–1}, colorless crystal. CCDC-909087 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

(11) For recent examples, see: (a) Varga, S.; Jakab, G.; Drahos, L.; Holczbauer, T.; Czugler, M.; Soós, T. *Org. Lett.* **2011**, *13*, 5416–5419. (b) Wang, L.-L.; Peng, L.; Bai, J.-F.; Jia, L.-N.; Luo, X.-Y.; Huang, Q.-C.; Xu, X.-Y.; Wang, L.-X. *Chem. Commun.* **2011**, *47*, 5593–5595. (c) Ma, A.; Ma, D. *Org. Lett.* **2010**, *12*, 3634–3637. (d) Zhao, G.-L.; Ibrahim, I.; Dziedzic, P.; Sun, J.; Bonneau, C.; Córdova, A. *Chem.—Eur. J.* **2008**, *14*, 10007–10011. (e) Enders, D.; Hüttl, M. R. M.; Grondal, C.; Raabe, G. *Nature* **2006**, *441*, 861–863.

Scheme 2. Plausible Reaction Mechanism for the Double-Michael Reaction



Scheme 3. Plausible Reaction Mechanism for the Pictet–Spengler Reaction



To explain the stereoselectivity of the reactions, plausible mechanisms were proposed as shown in Scheme 2 and Scheme 3. Initially, iminium formation of **4a** with catalyst **IV** provide the iminium intermediate **A**, followed by the nitro-Michael addition of the nitroalkane **3**, triggered by DABCO, from the *re* face under the control of the catalyst to give intermediate **B**, which could then undergo the subsequent Michael reaction to provide **5a** (Scheme 2).

Treatment of adduct **5a** with tryptamines **6a** and TFA afforded the Pictet–Spengler adducts (**E** or/and **F**) (Scheme 3). Since the stereogenic center formed in the Pictet–Spengler reaction is well-known to be subject to epimerization,¹⁴ the high diastereoselectivity of the cascade Pictet–Spengler–lactamization is probably governed by the differential rates of lactamization of intermediates **E** and **F**. As such, the predominate formation of **7a** arose from **E** via the lesser sterically bulky transition state **T1**, while another pathway from **F** toward **8a** was encumbered owing to the significant steric hindrance in transition state **T2**.

In summary, we have achieved an organocatalytic double-Michael reaction and Pictet–Spengler–lactamization of (*E*)-ethyl 6-nitrohex-2-enoate, α,β -unsaturated aldehydes, and 2-(1*H*-indol-3-yl)ethanamine and provided a facile entry to the dodecahydrobenz[*a*]indolo[3,2-*h*]quinolizine system with five contiguous stereogenic centers. The mild reaction conditions at ambient temperatures as well as the one-pot operation further manifest the merit of this strategy. The highly enantioselective transformation and the highly functionalized pentacyclic benzindolo-quinolizine products render this reaction sequence as a potential protocol for future synthetic applications. The structures as well as the absolute configurations of the products were unambiguously confirmed by X-ray crystallographic analysis of the appropriate adducts. Further work is underway to elaborate the synthetic applications of this procedure.

Acknowledgment. We acknowledge the financial support for this study from the National Science Council, Taiwan, ROC. Thanks to the instrument center of the National Science Council for analyses of compounds.

Supporting Information Available. Experimental procedures and characterization data for the new compounds and X-ray crystallographic data for compounds (–)-**7a** and (–)-**7c** (CIF). This material is available free of charge via the Internet at <http://pubs.acs.org>.

- (14) (a) Van Linn, M. L.; Cook, J. M. *J. Org. Chem.* **2010**, *75*, 3587. (b) Fang, H.; Wu, X.; Nie, L.; Dai, X.; Chen, J.; Cao, W.; Zhao, G. *Org. Lett.* **2010**, *12*, 5366–5369. (c) Zhang, W.; Franzen, J. *Adv. Synth. Catal.* **2010**, *352*, 499–518. (d) Shi, X. X.; Liu, S. L.; Xu, W.; Xu, Y. L. *Tetrahedron: Asymmetry* **2008**, *19*, 435. (e) Han, D. M.; Försterling, F. H.; Deschamps, J. R.; Parrish, D.; Liu, X. X.; Yin, W. Y.; Huang, S. M.; Cook, J. M. *J. Nat. Prod.* **2007**, *70*, 75. (f) Jiang, W. Q.; Sui, Z. H.; Chen, X. *Tetrahedron Lett.* **2002**, *43*, 8941. (g) Cox, E. D.; Hamaker, L. K.; Li, J.; Yu, P.; Czerwinski, K. M.; Deng, L.; Bennett, D. W.; Cook, J. M. *J. Org. Chem.* **1997**, *62*, 44.

The authors declare no competing financial interest.